| Literature DB >> 24531260 |
Abstract
Exposure to extreme altitude presents many physiological challenges. In addition to impaired physical and cognitive function, energy imbalance invariably occurs resulting in weight loss and body composition changes. Weight loss, and in particular, loss of fat free mass, combined with the inherent risks associated with extreme environments presents potential performance, safety, and health risks for those working, recreating, or conducting military operations at extreme altitude. In this review, contributors to muscle wasting at altitude are highlighted with special emphasis on protein turnover. The article will conclude with nutritional strategies that may potentially attenuate loss of fat free mass during high altitude exposure.Entities:
Mesh:
Year: 2014 PMID: 24531260 PMCID: PMC3942726 DOI: 10.3390/nu6020665
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Body composition changes at altitude.
| Reference | Conditions | Altitude (m) | Days at Altitude | Total Weight Loss (kg) | Body Composition Method | Body Fat Loss (kg) | FFM * Loss (kg) | % Weight Loss as FFM | |
|---|---|---|---|---|---|---|---|---|---|
| Boyer and Blume [ | 14 ** | Field | <5400 | 23 | 1.9 | Skinfolds | 1.34 | 0.56 | 29.5 |
| Rose | 8 males | Hypobaric chamber | Up to 8846 | 38 | 7.4 | Densitometry | 2.51 | 5.05 | 66.8 |
| Fulco | 16 males | Field | 3700–4300 | 16 | 5.9 | Densitometry | 3.46 | 2.44 | 41.4 |
| Westerterp | 3 male | Field | 5300–8872 | 30 † | 2.2 | Skinfolds | 1.4 | 0.8 | 36.4 |
| Westerterp | 4 male | Field | 6542 | 21 | 4.9 | Skinfolds | 3.5 | 1.3 | 27.0 |
| Pulfrey and Jones [ | 5 male | Field | 5900–8046 | 40 † | 3.7 | Skinfolds | 0.9 | 1.9 | 51.4 |
| Armellini | 10 male | Field | ≥4500 | 16 | 3.3 | Bioelectrical impedance | 2.2 | 1.1 | 33.3 |
| Tanner | 5 male | Field | 2200–4300 | 21 | 4.2 | Densitometry | 3.2 | 1.0 | 23.0 |
| Wing-Gaia | 10 male 8 female | Field | 2835–5364 | 13 | Control: 1.9 | Ultrasound skinfolds | 0.6 | 1.2 | 66.0 |
* Fat free mass; ** Gender not specified; † Study period was day 17–25 [2] and day 30–38 [9]; ‡ Supplemented with leucine (7 g/day) [37].
Figure 1A simplified schematic diagram of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway and proposed cellular regulation of muscle protein synthesis in response to hypoxia, caloric restriction, insulin, muscle contraction, and leucine. Proteins labeled as gray are positive regulators of mTORC1 and/or muscle protein synthesis and proteins labeled black are negative regulators of mTORC1 and/or muscle protein synthesis. TSC1, tuberous sclerosis complex 1; TSC2, tuberous sclerosis complex 2; Rheb, Ras-homologue enriched in brain; REDD1, gene regulated in DNA damage responses and development; AMPKα, AMP-activated protein kinase alpha; PRAS40, proline-rich Akt substrate 40; Raptor, regulatory associated protein of mTOR; S6K1, p70 ribosomal S6 kinase 1; rpS6, ribosomal protein S6; eEF2, eukaryotic elongation factor 2; 4E-BP1, 4E binding protein 1; eIF-4F, eukaryotic initiation factor 4F; PA, phosphatidic acid; Akt, protein kinase B.